Adaptimmune Therapeutics
$4.609876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$4.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.86 (-15.96%) Today
+$0.07 (+1.55%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell ADAP and other stocks, options, and ETFs commission-free!
About ADAP
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. The listed name for ADAP is Adaptimmune Therapeutics plc American Depositary Shares.
Employees
400
Headquarters
Abingdon, Oxfordshire
Founded
2014
Market Cap
700.62M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.58M
High Today
$5.38
Low Today
$4.51
Open Price
$5.28
Volume
2.94M
52 Week High
$13.40
52 Week Low
$0.709
Collections
Analyst Ratings
50%
of 8 ratings
Buy
50%
Hold
50%
Sell
0%
ADAP Earnings
-$0.33
-$0.22
-$0.11
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Nov 4, Pre-Market